An extract of bark from the tropical rainforest plant Byrsonima crassifolia was screened for inhibition of diubiquitin formation by the human ubiquitin-conjugating enzyme E2-25K. Activity assays with both the full-length enzyme and a truncated, active catalytic UBC domain revealed that the extract contained inhibitory properties. Separation of the extract into individual components and additional screens identified vitexin as the active inhibitor. An IC 50 for vitexin was calculated to be approximately 0.5 mM. Molecular modeling simulations were used to predict the mode of inhibition and NMR spectra were used to confirm the binding site of vitexin to E2-25K.
The ubiquitin-proteasome system (UPS) is one of the primary means by which eukaryotic cells degrade and recycle proteins. The proteasome recognizes and proteolytically degrades target proteins that have been tagged with a covalently-linked chain of the small protein ubiquitin. Conjugation of a target protein with ubiquitin requires a multi-step, multi-enzyme process. The first step is the ATP-dependent formation of a thioester bond between the C-terminal Gly76 residue of ubiquitin and an E1 ubiquitin-activating enzyme [1] . Interaction between the E1 and an E2 ubiquitin-conjugating enzyme mediates transfer of the covalently-linked ubiquitin to a conserved cysteine residue on the E2. The formation of an isopeptide bond between the ubiquitin C-terminal carboxylate group and the -amino group of a lysine residue on the target protein is catalyzed through the actions of the E2 and/or E3 (ubiquitin-ligase) enzymes. Subsequent addition of ubiquitin molecules to the Lys48 residue of the conjugated ubiquitin builds a polyubiquitin chain that is recognized by the 19S subunit of the proteasome. Deubiquitinating enzymes remove and break down the polyubiquitin chain while the target protein is degraded by the proteasome 20S subunit [2, 3] .
E2-25K was identified as a ubiquitin-conjugating enzyme which was able to synthesize free Lys48-linked polyubiquitin chains in the absence of an E3 ligase or protein target [4] . It is unique among mammalian E2s in the presence of an ubiquitin-associated (UBA) domain in addition to the conserved catalytic (UBC) domain. The structure of E2-25K revealed that there are interactions between the domains which may be responsible for directing chain linkage specificity and enzyme processivity [5, 6] .
Many neurological disorders are characterized by aggregates of misfolded proteins [7] . Typically the problem of misfolding is dealt with by the cell through molecular chaperones and the UPS. E2-25K has been identified as a key E2 involved in the clearance of misfolded proteins as they emerge from the endoplasmic reticulum [8, 9] , interacting with such membrane-bound E3s as gp78 and MARCHVII/axotrophin. Consistent with this role, E2-25K is upregulated in Alzheimer's Disease, has been identified as a huntingtin binding protein (huntingtin is the key protein mutated in Huntington's Disease) [10] , and is found to co-localize with huntingtin intranuclear inclusion bodies [11] .
Studies with E2-25K in model systems for both Alzheimer's Disease and Huntington's Disease demonstrate that the presence of a full-length, active E2-25K is necessary for the neurotoxic effects of Aβ amyloid [12, 13] and expanded polyglutamine peptides [11] . Because E2-25K is implicated in the development of at least two major neurodegenerative diseases, it presents a novel target for drug therapy.
We screened a series of tropical rainforest plant extracts for their ability to inhibit the synthesis of polyubiquitin chains by E2-25K. A crude acetone extract of bark from Byrsonima crassifolia caused complete inhibition of diubiquitin formation by both full-length E2-25K and the truncated, active, catalytic UBC domain, and was selected for further analysis. Byrsonima crassifolia (L.) Kunth (Malpighiaceae) is a medicinal tree that ranges from Mexico south to Peru and Paraguay as well as the Caribbean [14] . B. crassifolia extracts have exhibited many medicinal effects [15] including antibacterial, antifungal, anti-inflammatory [16] , antioxidant [17] , spasmogenic, antileishmanial, and trypanocidal activities; and have been shown to be rich in polyphenolics [18] [19] [20] .
The extract was separated into fractions and maximum inhibitory activity was determined by diubiquitin synthesis assays to be contained in fraction F40 (Supplemental Figure 1 ). Vitexin (8-glucopyranosyl-4',5,7-trihydroxyflavone) was isolated and identified by NMR analysis [21] as the active component in inhibition of the enzyme (Supplemental Figure 2 ). Vitexin ( Figure 1 ) has been isolated from Vitex littoralis, Adonis spp., Cyathea spp., Larix spp., Lespedeza spp., Prosopsis spp., and many other plant species [22] , and has shown hypotensive, antiinflammatory, antispasmodic [23, 24] , goitrogenic [25] , antidiabetic [26] , antitumor [27] , and hypoxia-inducible factor-1α inhibitory [28] activities. The synthesis of free Lys48-linked diubiquitin chains by E2-25K was used to assess the effectiveness of vitexin as an inhibitor, and an approximate IC 50 was determined from these assays. SDS-PAGE was used to visualize and monitor the decrease in diubiquitin chain synthesis as a function of vitexin concentration ( Figure 2 ). Gels were scanned and the intensities of the diubiquitin bands in the presence of inhibitor were digitally determined and compared to the control assay. The IC 50 was calculated to be approximately 0.20% -0.33% (0.38 -0.63 mM).
In order to examine potential sites for interaction of vitexin with E2-25K, a molecular docking analysis was carried out using the crystal structure of E2-25K (PDB: 1YLA) as a model [29] . Three potential binding sites on E2-25K were identified ( Table 1 ).
The lowest-energy docking site for vitexin was Site 2. Mapping the amino acid residues involved in the interaction revealed that the site partially overlaps with the E1 ubiquitin-activating enzyme binding site near the Nterminal helix 1, sheet 1 and the 12 loop [30] ( Figure  3A) . Site 1 and Site 3 are located at the interface between the catalytic domain (UBC) and the ubiquitin-associated domain (UBA), and in a hydrophobic pocket, respectively.
NMR titration experiments were conducted to determine amino acid residues in E2-25K that are perturbed upon binding to vitexin. Because chemical shifts are extremely sensitive reporters of the local magnetic environment, ligand binding generally alters the chemical shifts of nearby backbone and sidechain resonances. This approach is sensitive to weak binding in the millimolar range [31] . When stoichiometric amounts of unlabeled vitexin were added to 15 This is the first published small molecule inhibitor of an E2 ubiquitin-conjugating enzyme whose mode of action involves binding to a known E1 interaction site. Preventing E1/E2 binding is predicted to interfere with the formation of an activated E2~Ub conjugate, leading to decreased ubiquitination of target proteins. One additional small molecule inhibitor, leucettamol A has been reported to inhibit activity of the heterodimeric E2 complex Ubc13/Uev1A by blocking dimer formation [32] . Additional studies are required to confirm the mode of action for vitexin and to elucidate the structure of the enzyme/inhibitor complex. This information will provide helpful clues for design of a more effective inhibitor.
Experimental

Extraction and Identification of Vitexin:
Air-dried bark of Byrsonima crassifola (969 g), collected from the San Luis Biological Station in the Puntarenas province of Costa Rica, was extracted with refluxing acetone for six hours. The solvent was evaporated in vacuo to give an oily, dark, brownish resin (117 g). Twenty-five grams of the crude acetone extract was subjected to fractionation by flash column chromatography using silica gel as the stationary phase, and eluted successively with n-hexane/ethyl acetate (9:1 to 1:1) and ethanol to give 73 fractions (F1-F73). Amorphous solids in fraction F40 were filtered and washed first with methanol, then with chloroform to give 154.4 mg of purified compound. An NMR sample was dissolved in DMSO (5 mg/ml) and 1D NMR data were obtained on a 500 MHz Varian INOVA Spectrometer at 25 °C using VNMR (Varian) pulse sequences. The NMR data were processed and analyzed using MestreC or Mnova NMR (Mestrelab Research, Escondido, CA, USA). The compound isolated from fraction F40 was identified as vitexin by comparison of its 1 H and 13 C NMR data to those previously reported [21] .
Plasmids:
The catalytic domain (residues M1-S159) of E2-25K was PCR amplified using full-length E2-25K in a pET30b expression vector as a template, and subcloned into pET28b for expression (to change antibiotic resistance from ampicillin to kanamycin). The clone was sequence verified (Functional Biosciences, Inc) and named UBC. Ubiquitin D77 and K48C mutants were created by sitedirected mutagenesis of a pET28b plasmid expressing wild-type human ubiquitin. Clones were sequence verified (Functional Biosciences, Inc) and named Ub-D77 and Ub-K48C, respectively.
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Protein expression and purification:
The E2-25K, UBC domain, Ub-D77, and Ub-K48C plasmids were expressed and purified as previously described [6] . Fractions from a Ni 2+ -column (GE Healthcare) containing E2-25K were pooled and dialyzed against enterokinase buffer (20 mM Tris HCl, pH 7.4, 50 mM NaCl, 2 mM CaCl 2 ). Digestion with enterokinase was allowed to proceed overnight and protein was purified by ion-exchange chromatography on a Mono Q (GE Healthcare) column. Fractions containing digested E2-25K were pooled, dialyzed against assay buffer (20 mM Tris HCl, pH 8.0, 50 mM NaCl) and concentrated by ultra-filtration (Amicon) to approximately 1.6 mg/ml. Purified E2-25K UBC domain was dialyzed against assay buffer and concentrated by ultra-filtration to approximately 4.3 mg/ml. Purified Ub-K48C and Ub-D77 were dialyzed against 50 mM Tris-HCl, pH 8.0, 0.1 mM EDTA and 0.5 mM DTT and concentrated by ultrafiltration to approximately 4.1 and 1.3 mg/ml, respectively. 15 N-labeled E2-25K was prepared as described above except that transformed BL21(DE3) E. coli were grown at 37°C to an OD 600 of ~0.6 in M9 medium containing 35 μg/ml kanamycin and 1 g/L 15 NH 4 Cl. The temperature was lowered to 18°C after induction and cultures were grown overnight. Purified, digested E2-25K was dialyzed against 50 mM Na phosphate buffer, pH 6.5, and concentrated by ultrafiltration to ~12 mg/ml. All final NMR samples contained 0.12 mM sodium 4,4-dimethyl-4-silapentane-1-sulfonate (DSS), and 0.9% (v/v) NaN 3 in 90% H 2 O/10% D 2 O.
Isotopic labeling:
NMR Binding Experiments:
Binding of 15 N-labeled E2-25K UBA domain to vitexin was examined by solution NMR using 15 N-HSQC chemical shift perturbation mapping [33] . Increasing amounts of 1% vitexin stock solution (25.7 mM in DMSO) were titrated by 25 μL aliquots into 15 N-labeled E2-25K (0.55 mM). Specific changes in chemical shift values were used to identify amino acids whose chemical environment was altered upon binding [31] .
Protein NMR spectroscopy: NMR spectra were collected at 25ºC on a Varian 800 MHz (18.7 T field) INOVA NMR spectrometer using a room temperature triple-resonance probe with triaxial pulsed field gradient capability. Pulse sequences were those provided in the Varian BioPack. 1 H chemical shifts were referenced using sodium 4,4dimethyl-4-silapentane-1-sulfonate (DSS) as an internal reference. 15 N chemical shifts were referenced indirectly to liquid ammonia, using the appropriate frequency ratios [34] . NMR spectra were processed using NMRPipe [35] . NMRView [36] was used for visualization and chemical shift assignments of NMR data.
Polyubiquitin Chain Assay:
The polyubiquitin chain synthesis assay was adapted from work performed by Piotrowski et al. [37] , and designed to generate Lys48linked chains which were limited in length to diubiquitin (DiUb). The assay contained either 20 µM E2-25K or E2-25K UBC domain along with 0.15 mM Ub-D77, 0.15 mM Ub-K48C, 4 mM Mg-ATP Solution, 0.2 µM E1 activating enzyme (BostonBiochem), 10 mM phosphocreatine, 0.6 unit/ml of inorganic phosphokinase and creatine phosphokinase, 10 mM phosphocreatine and 0.5 mM DTT. 25 μL aliquots of the assay mixture were placed in separate tubes and combined with 2 μL of plant extract, extract fractions, or vitexin stock solutions.
Assays were conducted at 37C for 3 hours, and analyzed by SDS-PAGE using 15% polyacrylamide gels. Concentrations of purified vitexin stock solutions in DMSO were 0.17% (0.32 mM), 0.20% (0.38 mM), 0.25% (0.48 mM), 0.33% (0.63 mM), and 0.50% (0.95 mM).
Determining IC 50 : Polyacrylamide gels were stained with Coomassie blue and imaged using a Kodak EDAS 290 digital camera. Band intensities were determined using Kodak 1D v.3.5.4 software (Eastman Kodak) and used to measure percent response for each assay. Percent response was calculated by subtracting the intensity of the diubiquitin band synthesized in the presence of inhibitor from that synthesized in the absence of inhibitor (control), and dividing by the control: ([DiUb Intensity control -DiUb Intensity inhibitor ]/DiUb Intensity control )*100. A linear fit of the plot of % response versus inhibitor concentration was used to estimate the inhibitor concentration at which a response of 50% would be observed. 39] . The PDB crystal structure atomic coordinates of the ubiquitin conjugating enzyme E2-25K (PDB: 1YLA) were imported. All water molecules were removed from the structure. The entire surface of each structure and all cavities were used in the docking studies. Different orientations of the ligands were searched and ranked based on their energy scores. The RMSD threshold for multiple cluster poses was set at < 1.00Å. The docking algorithm was set at maximum iterations of 1500 with a simplex evolution population size of 50 and a minimum of 30 runs for each ligand.
